Rosanna Fiallo-Scharer, MD

Associate Professor, Pediatrics (Endocrinology); Program Director, Diabetes, Children's Hospital of Wisconsin

Locations

Children's Hospital
9000 W Wisconsin Ave.
Milwaukee, WI 53226

Contact Information

Education

MD, Universidad Nacional Pedro Henriquez Urena Escuela de Medicina, 1989
Residency, Pediatrics, Monmouth Med Center, Long Beach, NJ, 1995
Fellowship, Pediatric Endocrinology, New York and Presbyterian Hospitals-Cornell Campus, 1998

Biography

Board Certifications: American Board of Pediatrics-Pediatric Endocrinology

Research Interests

Diabetes, adrenal disorders and disorders of sexual differentiation

The overall goal of my research is to improve the health and overall quality of life of those living with type 1 diabetes by identifying specific barriers to diabetes self-management in 6 distinct areas of self-care and tailoring interventions to each patient’s self- identified barriers.

Over the past 12 years I have been involved in collaborative research aimed at identifying genes and environmental factors involved in the determination of type 1 diabetes susceptibility and studying the applications of new technologies to improve clinical outcomes and quality of life in patients living with type 1 diabetes. During my almost 11 year appointment at the Barbara Davis Center for Diabetes and the University of Colorado Denver, I collaborated along with Dr. H Peter Chase with other diabetes researchers in academic centers across the country in conducting the first pediatric studies of Continuous Glucose Monitoring (CGM) technology applications in the pediatric population. My participation in the NIH-funded Diabetes Research in Children Network (DirecNet) consortium and the JDRF-funded Artificial Pancreas Project resulted in numerous publications including the first rigorously designed randomized controlled trial of CGM efficacy across a wide age spectrum (Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes. N Engl J Med 359;14 October 2, 2008). The study was powered to independently assess efficacy of CGM use for diabetes management in 3 distinct age groups: young children (8-14), adolescents and young adults (15-24) and older adults (>25). The study had a great impact in disseminating CGM use in clinical practices by facilitating insurance coverage of the technology.

Since I joined the faculty at MCW in November of 2012, I have been involved with the TrialNet Natural History study and the Type 1 diabetes exchange registry. The T1D exchange registry is maintaining a database of information obtained from a consortium of 67 clinical diabetes centers across the US. The rich dataset of the registry provides an opportunity to address numerous issues of relevance to clinicians and patients, including assessments of associations between patient characteristics and diabetes management factors with outcomes. Data recently published by the registry shows that less than 50% of patients of all ages are meeting the recommended goals for HbA1c and other parameters known to prevent long term complications. This highlights an urgent need to modify the chronic health care model in order to promote improved self-management. My main research focus for the next 3 years will be in a collaboration with researchers at UW Madison to implement a patient-centered approach to assigning diabetes management resources based on unique patient needs. This study is sponsored by a $2.1 million grant from the Patient Centered Outcomes Research Institute (PCORI).

Impact of family-centered tailoring of pediatric diabetes self-management resources.

(Fiallo-Scharer R, Palta M, Chewning BA, Rajamanickam V, Wysocki T, Wetterneck TB, Cox ED.) Pediatr Diabetes. 2019 Nov;20(7):1016-1024.
Design and baseline data from a PCORI-funded randomized controlled trial of family-centered tailoring of diabetes self-management resources.

(Fiallo-Scharer R, Palta M, Chewning BA, Wysocki T, Wetterneck TB, Cox ED.) Contemp Clin Trials. 2017 07;58:58-65.
Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers.

(Onengut-Gumuscu S, Chen WM, Burren O, Cooper NJ, Quinlan AR, Mychaleckyj JC, Farber E, Bonnie JK, Szpak M, Schofield E, Achuthan P, Guo H, Fortune MD, Stevens H, Walker NM, Ward LD, Kundaje A, Kellis M, Daly MJ, Barrett JC, Cooper JD, Deloukas P, Type 1 Diabetes Genetics Consortium, Todd JA, Wallace C, Concannon P, Rich SS.) Nat Genet. 2015 Apr;47(4):381-6.
The T1D Exchange clinic registry.

(Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA, T1D Exchange Clinic Network.) J Clin Endocrinol Metab. 2012 Dec;97(12):4383-9.
The landmark JDRF continuous glucose monitoring randomized trials: a look back at the accumulated evidence.

(Ruedy KJ, Tamborlane WV, Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group.) J Cardiovasc Transl Res. 2012 Aug;5(4):380-7.
Rare and functional SIAE variants are not associated with autoimmune disease risk in up to 66,924 individuals of European ancestry.

(Hunt KA, Smyth DJ, Balschun T, Ban M, Mistry V, Ahmad T, Anand V, Barrett JC, Bhaw-Rosun L, Bockett NA, Brand OJ, Brouwer E, Concannon P, Cooper JD, Dias KR, van Diemen CC, Dubois PC, Edkins S, Fölster-Holst R, Fransen K, Glass DN, Heap GA, Hofmann S, Huizinga TW, Hunt S, Langford C, Lee J, Mansfield J, Marrosu MG, Mathew CG, Mein CA, Müller-Quernheim J, Nutland S, Onengut-Gumuscu S, Ouwehand W, Pearce K, Prescott NJ, Posthumus MD, Potter S, Rosati G, Sambrook J, Satsangi J, Schreiber S, Shtir C, Simmonds MJ, Sudman M, Thompson SD, Toes R, Trynka G, Vyse TJ, Walker NM, Weidinger S, Zhernakova A, Zoledziewska M, Type 1 Diabetes Genetics Consortium, UK Inflammatory Bowel Disease (IBD) Genetics Consortium, Wellcome Trust Case Control Consortium, Weersma RK, Gough SC, Sawcer S, Wijmenga C, Parkes M, Cucca F, Franke A, Deloukas P, Rich SS, Todd JA, van Heel DA.) Nat Genet. 2011 Dec 27;44(1):3-5.
The interrelationships of glycemic control measures: HbA1c, glycated albumin, fructosamine, 1,5-anhydroglucitrol, and continuous glucose monitoring.

(Beck R, Steffes M, Xing D, Ruedy K, Mauras N, Wilson DM, Kollman C, Diabetes Research in Children Network (DirecNet) Study Group.) Pediatr Diabetes. 2011 Dec;12(8):690-5.
Health utilities for children and adults with type 1 diabetes.

(Lee JM, Rhee K, O'grady MJ, Basu A, Winn A, John P, Meltzer DO, Kollman C, Laffel LM, Lawrence JM, Tamborlane WV, Wysocki T, Xing D, Huang ES, JDRF Continuous Glucose Monitoring Study Group.) Med Care. 2011 Oct;49(10):924-31.
Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring.

(Xing D, Kollman C, Beck RW, Tamborlane WV, Laffel L, Buckingham BA, Wilson DM, Weinzimer S, Fiallo-Scharer R, Ruedy KJ, Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group.) Diabetes Technol Ther. 2011 Mar;13(3):351-8.
Factors predictive of severe hypoglycemia in type 1 diabetes: analysis from the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized control trial dataset.

(Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Fiallo-Scharer R, Cheng J, Beck RW, Buckingham BA, Chase HP, Kollman C, Laffel L, Lawrence JM, Mauras N, Tamborlane WV, Wilson DM, Wolpert H.) Diabetes Care. 2011 Mar;34(3):586-90.
Hemoglobin A1c and mean glucose in patients with type 1 diabetes: analysis of data from the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial.

(Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Wilson DM, Xing D, Beck RW, Block J, Bode B, Fox LA, Hirsch I, Kollman C, Laffel L, Ruedy KJ, Steffes M, Tamborlane WV.) Diabetes Care. 2011 Mar;34(3):540-4.
Validation of measures of satisfaction with and impact of continuous and conventional glucose monitoring.

(Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group.) Diabetes Technol Ther. 2010 Sep;12(9):679-84.

Rosanna Fiallo-Scharer, MD